Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Long‐Yun Ye

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0005-7388-9212; OpenAlex author ID A5087358843. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
43
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 4 papers · 2023: 5 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 21

  1. Mucosal-associated invariant T cells promote PDAC progression via TL1A-CSF-1 axis. Co-author DOI 10.1007/s00535-026-02468-4↗
  2. Age and sex-dependent tumor microbiome programs shape pancreatic cancer prognosis. Co-author DOI 10.1016/j.isci.2026.116542↗
  3. Genomic mutation and Clinicopathological features of KRAS wild-type tumors in Chinese cohort with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2025.111048↗
  4. Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation. Co-author DOI 10.1186/s13046-025-03563-9↗
  5. The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancer. First author DOI 10.1016/j.csbj.2024.09.032↗
  6. The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer. Co-author DOI 10.1038/s41419-024-06589-7↗
  7. Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway. Last author DOI 10.3724/abbs.2023286↗
  8. Tissue-resident CXCR4+ macrophage as a poor prognosis signature promotes pancreatic ductal adenocarcinoma progression. First author DOI 10.1002/ijc.34468↗
  9. Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2023.216411↗
  10. Knockdown of TACC3 inhibits tumor cell proliferation and increases chemosensitivity in pancreatic cancer. Co-author DOI 10.1038/s41419-023-06313-x↗
  11. Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/febs.16879↗
  12. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer. First author DOI 10.3724/abbs.2023045↗
  13. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  14. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  15. Innate immunity in pancreatic cancer: Lineage tracing and function. Co-author DOI 10.3389/fimmu.2022.1081919↗
  16. Neoadjuvant therapy alters the immune microenvironment in pancreatic cancer. First author DOI 10.3389/fimmu.2022.956984↗
  17. Activation of the PX1/IL-1β axis in CD41+/CD62P+ platelets enhances pancreatic ductal adenocarcinoma invasion and metastasis Co-author DOI 10.21203/rs.3.rs-307202/v1↗
  18. Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. First author DOI 10.3390/cancers13153678↗
  19. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective. Co-author DOI 10.1016/j.csbj.2020.11.018↗
  20. Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells. Co-author PMID 32774728↗
  21. Hypoxia-inducible factor 1α expression and its clinical significance in pancreatic cancer: a meta-analysis. Co-author DOI 10.1016/j.pan.2014.06.008↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kaizhou Jin · 14 shared papers, 2022–2026 · strength 2.85
  2. Xianjun Yu · 15 shared papers, 2020–2026 · strength 2.70
  3. Weiding Wu · 13 shared papers, 2022–2026 · strength 2.62
  4. Qinglin Fei · 9 shared papers, 2022–2026 · strength 1.78
  5. Saimeng Shi · 9 shared papers, 2022–2025 · strength 1.77
  6. Tianjiao Li · 8 shared papers, 2020–2024 · strength 1.21
  7. Duancheng Guo · 5 shared papers, 2023–2025 · strength 1.13
  8. Huiru Zhang · 5 shared papers, 2022–2024 · strength 0.91
  9. Zhenyu Liao · 6 shared papers, 2021–2023 · strength 0.86
  10. Xuan Lin · 5 shared papers, 2020–2023 · strength 0.62
  11. Huaxiang Xu · 5 shared papers, 2020–2022 · strength 0.57
  12. Liang Liu · 4 shared papers, 2020–2022 · strength 0.45
  13. Heli Gao · 3 shared papers, 2020–2022 · strength 0.33
  14. Wuhu Zhang · 3 shared papers, 2020–2022 · strength 0.33
  15. Wenquan Wang · 3 shared papers, 2020–2022 · strength 0.33
  16. Wei Chen · 1 shared paper, 2022 · strength 0.26
  17. Zhiwen Xiao · 2 shared papers, 2022 · strength 0.26
  18. Shuaiwu Luo · 1 shared paper, 2026 · strength 0.25
  19. Jun Yang · 1 shared paper, 2026 · strength 0.25
  20. Pengcheng Zhou · 1 shared paper, 2026 · strength 0.25
  21. Enliang Li · 1 shared paper, 2026 · strength 0.25
  22. Hao Li · 2 shared papers, 2021–2022 · strength 0.24
  23. Chen Liu · 1 shared paper, 2024 · strength 0.24
  24. Xianjun Yu · 1 shared paper, 2025 · strength 0.24
  25. Jianhui Yang · 1 shared paper, 2025 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.